New Effective Lymphoma Treatment Approved by FDA

Approval for an investigational drug to treat Hodgkin’s lymphoma in patients who have already had a stem cell transplant was unanimously approved on Thursday by an FDA advisory panel.

As per the details of the arrangement, the drug will be utilized for patients with relapsed or resistant systematic anaplastic large cell lymphoma.

An FDA advisory panel voted unanimously Thursday to recommend accelerated approval for an investigational drug to treat Hodgkin lymphoma in patients who have already had a stem cell transplant, and for patients with relapsed or resistant systemic anaplastic large cell lymphoma. Brentuximab vedotin, which Seattle Genetics has already said it will market as Adcetris, is the combination of antibody and chemotherapy drug to effectively treat rare blood cancer. While the antibody binds the CD30-positive Reed-Sternberg cells, the monomethyl auristatin attacks the internal structure of the cells.

The FDA panel in question, the Oncologic Drugs Advisory Committee, voted it through with a 10-0 total. Much of the approval was based on the very successful trial that the company presented, during which three-quarters of the patients treated had at least a mild reduction in tumor burden while more than a third had an entire remission.

Considering the fact that no new agents have been approved for the treatment of Hodgkin’s lymphoma since the late 1970s, this could be a potentially monumental first step on the road to getting a proper lymphoma treatment on the market.

More Articles

More Articles

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Lymphoma is a life-threatening disease, but is very treatable in most cases. The 5-year survival for patients diagnosed with non-Hodgkin's...

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...